SCHEMBL4901659

SCHEMBL4901659

O=C(Nc1ccc(Nc2nccc(-c3cccnc3)n2)cc1)c1cccnc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 16/20 0.81
BCR P11274 15/20 0.81
PDGFRB P09619 9/20 0.81
PDGFRA P16234 9/20 0.81
PRKCA P17252 8/20 0.81
PRKCD Q05655 4/20 0.81
SRC P12931 4/20 0.81
PRKD3 O94806 1/20 0.72
PRKCG P05129 1/20 0.72
PRKCB P05771 1/20 0.72
PRKCH P24723 1/20 0.72
PRKCI P41743 1/20 0.72
PRKCE Q02156 1/20 0.72
PRKCQ Q04759 1/20 0.72
PRKCZ Q05513 1/20 0.72
PRKD1 Q15139 1/20 0.72
HDAC1 Q13547 1/20 0.68
EGFR P00533 2/20 0.67
ABL2 P42684 1/20 0.65
MAPK8 P45983 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4903275 0.94 ABL1 (0.81) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL4904939 0.93 ABL1 (0.71) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL1522 0.90 ABL1 (1.00) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL4905733 0.89 PDGFRA (0.77) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL4903136 0.89 PDGFRA (0.82) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL4899630 0.88 ABL1 (0.64) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL2004455 0.86 PDGFRA (0.91) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL12034590 0.86 PDGFRA (0.77) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL3518422 0.86 IKBKB (0.64) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL4897346 0.86 ABL1 (0.67) ABL1BCRPDGFRBPDGFRAPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP ABL1 2843/4885BCR 2315/4885PDGFRB 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.